Literature DB >> 17627610

Comparable potency of IFNalpha2 and IFNbeta on immediate JAK/STAT activation but differential down-regulation of IFNAR2.

Zrinka Marijanovic1, Josiane Ragimbeau, José van der Heyden, Gilles Uzé, Sandra Pellegrini.   

Abstract

Type I IFNs (interferons) (IFNalpha/beta) form a family of related cytokines that control a variety of cellular functions through binding to a receptor composed of IFNAR (IFNalpha receptor subunit) 1 and 2. Among type I IFNs, the alpha2 and beta subtypes exhibit a large difference in their binding affinities to IFNAR1, and it was suggested that high concentrations of IFNAR1 may compensate for its low intrinsic binding affinity for IFNalpha2. We tested whether receptor-proximal signalling events are sensitive to IFNAR1 surface concentration by investigating the relationship between relative IFNAR1/IFNAR2 surface levels and IFNalpha2 and IFNbeta signalling potencies in several cell lines. For this, we monitored the activation profile of JAK (Janus kinase)/STAT (signal transducer and activator of transcription) proteins, measured basal and ligand-induced surface decay of each receptor subunit and tested the effect of variable IFNAR1 levels on IFNalpha2 signalling potency. Our data show that the cell-surface IFNAR1 level is indeed a limiting factor for assembly of the functional complex, but an increased concentration of it does not translate into an IFNalpha/beta differential JAK/STAT signalling nor does it change the dynamics of the engaged receptor. Importantly, however, our data highlight a differential effect upon routing of IFNAR2. Following binding of IFNalpha2, IFNAR2 is internalized, but, instead of being routed towards degradation as it is when complexed to IFNbeta, it recycles back to the cell surface. These observations suggest strongly that the stability and the intracellular lifetime of the ternary complex account for the differential control of IFNAR2. Moreover, the present study opens up the attractive possibility that endosomal-initiated signalling may contribute to IFNalpha/beta differential bioactivities.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17627610      PMCID: PMC2267396          DOI: 10.1042/BJ20070605

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  44 in total

Review 1.  The Class II cytokine receptor (CRF2) family: overview and patterns of receptor-ligand interactions.

Authors:  Jerome A Langer; E Cali Cutrone; Sergei Kotenko
Journal:  Cytokine Growth Factor Rev       Date:  2004-02       Impact factor: 7.638

2.  Ligand-induced assembling of the type I interferon receptor on supported lipid bilayers.

Authors:  Peter Lamken; Suman Lata; Martynas Gavutis; Jacob Piehler
Journal:  J Mol Biol       Date:  2004-07-30       Impact factor: 5.469

Review 3.  The odd couple: signal transduction and endocytosis.

Authors:  D Teis; L A Huber
Journal:  Cell Mol Life Sci       Date:  2003-10       Impact factor: 9.261

4.  pH and the recycling of transferrin during receptor-mediated endocytosis.

Authors:  A Dautry-Varsat; A Ciechanover; H F Lodish
Journal:  Proc Natl Acad Sci U S A       Date:  1983-04       Impact factor: 11.205

5.  Distinct endocytic pathways regulate TGF-beta receptor signalling and turnover.

Authors:  Gianni M Di Guglielmo; Christine Le Roy; Anne F Goodfellow; Jeffrey L Wrana
Journal:  Nat Cell Biol       Date:  2003-05       Impact factor: 28.824

6.  The tyrosine kinase Tyk2 controls IFNAR1 cell surface expression.

Authors:  Josiane Ragimbeau; Elisabetta Dondi; Andrés Alcover; Pierre Eid; Gilles Uzé; Sandra Pellegrini
Journal:  EMBO J       Date:  2003-02-03       Impact factor: 11.598

7.  SCF(HOS) ubiquitin ligase mediates the ligand-induced down-regulation of the interferon-alpha receptor.

Authors:  K G Suresh Kumar; Weigang Tang; Abhilash K Ravindranath; William A Clark; Ed Croze; Serge Y Fuchs
Journal:  EMBO J       Date:  2003-10-15       Impact factor: 11.598

8.  Interferon-gamma inhibits interferon-alpha signalling in hepatic cells: evidence for the involvement of STAT1 induction and hyperexpression of STAT1 in chronic hepatitis C.

Authors:  Svetlana Radaeva; Barbara Jaruga; Won-Ho Kim; Theo Heller; T Jake Liang; Bin Gao
Journal:  Biochem J       Date:  2004-04-01       Impact factor: 3.857

9.  Monensin interrupts the recycling of low density lipoprotein receptors in human fibroblasts.

Authors:  S K Basu; J L Goldstein; R G Anderson; M S Brown
Journal:  Cell       Date:  1981-05       Impact factor: 41.582

10.  Differential tyrosine phosphorylation of the IFNAR chain of the type I interferon receptor and of an associated surface protein in response to IFN-alpha and IFN-beta.

Authors:  C Abramovich; L M Shulman; E Ratovitski; S Harroch; M Tovey; P Eid; M Revel
Journal:  EMBO J       Date:  1994-12-15       Impact factor: 11.598

View more
  39 in total

Review 1.  Cytokine-receptor interactions as drug targets.

Authors:  Gideon Schreiber; Mark R Walter
Journal:  Curr Opin Chem Biol       Date:  2010-07-07       Impact factor: 8.822

2.  CCR2 Signaling Selectively Regulates IFN-α: Role of β-Arrestin 2 in IFNAR1 Internalization.

Authors:  Dionna W Williams; Lauren C Askew; Elonna Jones; Janice E Clements
Journal:  J Immunol       Date:  2018-11-30       Impact factor: 5.422

3.  Receptor density is key to the alpha2/beta interferon differential activities.

Authors:  Ignacio Moraga; Daniel Harari; Gideon Schreiber; Gilles Uzé; Sandra Pellegrini
Journal:  Mol Cell Biol       Date:  2009-06-29       Impact factor: 4.272

4.  Stochastic receptor expression determines cell fate upon interferon treatment.

Authors:  Doron Levin; Daniel Harari; Gideon Schreiber
Journal:  Mol Cell Biol       Date:  2011-06-20       Impact factor: 4.272

5.  Interferon Beta and Interferon Alpha 2a Differentially Protect Head and Neck Cancer Cells from Vesicular Stomatitis Virus-Induced Oncolysis.

Authors:  Marlena M Westcott; Jingfang Liu; Karishma Rajani; Ralph D'Agostino; Douglas S Lyles; Mercedes Porosnicu
Journal:  J Virol       Date:  2015-05-20       Impact factor: 5.103

6.  A hot spot on interferon α/β receptor subunit 1 (IFNAR1) underpins its interaction with interferon-β and dictates signaling.

Authors:  Nicole A de Weerd; Antony Y Matthews; Phillip R Pattie; Nollaig M Bourke; San S Lim; Julian P Vivian; Jamie Rossjohn; Paul J Hertzog
Journal:  J Biol Chem       Date:  2017-03-13       Impact factor: 5.157

Review 7.  Autoreactive B cells in SLE, villains or innocent bystanders?

Authors:  Jennie A Hamilton; Hui-Chen Hsu; John D Mountz
Journal:  Immunol Rev       Date:  2019-10-21       Impact factor: 12.988

8.  Ligand-independent interaction of the type I interferon receptor complex is necessary to observe its biological activity.

Authors:  Christopher D Krause; Gina Digioia; Lara S Izotova; Junxia Xie; Youngsun Kim; Barbara J Schwartz; Olga V Mirochnitchenko; Sidney Pestka
Journal:  Cytokine       Date:  2013-07-03       Impact factor: 3.861

Review 9.  Structural and dynamic determinants of type I interferon receptor assembly and their functional interpretation.

Authors:  Jacob Piehler; Christoph Thomas; K Christopher Garcia; Gideon Schreiber
Journal:  Immunol Rev       Date:  2012-11       Impact factor: 12.988

10.  Dynamic expression profiling of type I and type III interferon-stimulated hepatocytes reveals a stable hierarchy of gene expression.

Authors:  Christopher R Bolen; Siyuan Ding; Michael D Robek; Steven H Kleinstein
Journal:  Hepatology       Date:  2014-02-18       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.